CGT Global

CGT Global was founded in 2010 to accelerate the cure and prevention of significant medical conditions at life-changing speed. CGT Global supports cell and gene therapies, commercialization of disease-specific treatments, medical research, clinical trials, precision/regenerative medicine, among other researchers and clinicians around the world who are developing and implementing revolutionary treatments and cures. CGT Global is currently the nations leading biospecimen provider of human primary cells, stem cells, human bone marrow, cord blood, peripheral blood, maternal blood, and disease-state products for academic, biotechnological, diagnostic, pharmaceutical and contract research organizations. CGT Global is registered with the U.S. Food and Drug Administration...

Stem cell isolation for research,maternal blood retrieval and processing,cell separation and isolation,full laboratory services,leukopaks,cord blood retrieval and processing,bone marrow collection and processing,peripheral blood collection and processing,immunophenotyping,human primary cells,customized projects,mobilized leukopaks,diseased blood collection,contract research organization,immune cells,cgtp & cgmp compliant,procurement,biospecimen,stem cells,mesenchymal,donor recruitment,employer testing,donor recruitment,and bulk cell isolation

Cgt global operates in the Biotechnology research industry.

Cgt global's revenue is 11m - 100m

Cgt global has 51 - 200 employees.